YU88602A - Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same - Google Patents
Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the sameInfo
- Publication number
- YU88602A YU88602A YU88602A YUP88602A YU88602A YU 88602 A YU88602 A YU 88602A YU 88602 A YU88602 A YU 88602A YU P88602 A YUP88602 A YU P88602A YU 88602 A YU88602 A YU 88602A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- pharmaceutical formulation
- substance
- hmg
- chemical synthesis
- coa reductase
- Prior art date
Links
Abstract
Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilised by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions. The present invention relates to a HMG-CoA reductase inhibitor which is stabilized by forming a homogeneous composition with a buffering substance or a basifying substance. This homogeneous composition is suitably used as the active substance in a pharmaceutical formulation for the treatment of hypercholesterolemia and hyperlipidemia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
YU88602 | 2000-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU88602A true YU88602A (en) | 2006-05-25 |
Family
ID=47748802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU88602A YU88602A (en) | 2000-06-09 | 2000-06-09 | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
Country Status (1)
Country | Link |
---|---|
YU (1) | YU88602A (en) |
-
2000
- 2000-06-09 YU YU88602A patent/YU88602A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL362764A1 (en) | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same | |
NZ511260A (en) | Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitor | |
IL187261A0 (en) | Crystals of the sodium salt of pravastatin | |
IS5891A (en) | New salts of HMG-CoA reductase inhibitors | |
ATE284396T1 (en) | METHOD FOR PROVIDING HIGH PURITY HMG-COA REDUCTASE INHIBITORS | |
WO2000048626A3 (en) | Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease | |
IL141785A0 (en) | A pharmaceutical composition containing an ap2 inhibitor | |
AU1510800A (en) | Process for the preparation of simvastatin and analogs thereof | |
AU2000250960A1 (en) | Stable pharmaceutical product and formulation | |
YU88602A (en) | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same | |
NZ535910A (en) | Preparation of amorphous HMG-CoA reductase inhibitors and hydrates thereof by dissolving a heterogeneous mixture of the enzyme in a hydroxylic solvent and freeze drying | |
RU2309141C2 (en) | AMORPHOUS HMG-KoA REDUCTASE INHIBITORS AND A METHOD FOR PREPARATION THEREOF | |
CO5611117A2 (en) | COMBINATION OF ORGANIC COMPOUNDS |